Based on input from an international panel of experts, this book provides first-hand experience of the challenges and opportunities facing the delivery of regenerative medicines to patients. It highlights key issues beyond science and clinical translation, such as finance and business models, intellectual property and regulatory landscapes as well as questions of how regenerative medicines will be evaluated for reimbursement. It also covers legal issues relevant to regulators, insurers, and investors as well as pharmaceutical and biotech researchers.
Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.